Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Mar 17;9(3):813.
doi: 10.3390/jcm9030813.

Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment"

Marta Ruiz-Ortega  1   2 , Raul R Rodrigues-Diez  1   2 , Carolina Lavoz  3 , Sandra Rayego-Mateos  4
Affiliations
Editorial

Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment"

Marta Ruiz-Ortega et al. J Clin Med. .

Abstract

Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the Journal of Clinical Medicine.

Keywords: biomarkers; chronic kidney disease; diabetic nephropathy; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

    1. Donate-Correa J., Luis-Rodríguez D., Martín-Núñez E., Tagua V.G., Hernández-Carballo C., Ferri C., Rodríguez-Rodríguez A.E., Mora-Fernández C., Navarro-González J.F. Inflammatory targets in diabetic nephropathy. J. Clin. Med. 2020;9:458. doi: 10.3390/jcm9020458. - DOI - PMC - PubMed
    1. Lavoz C., Rayego-Mateos S., Orejudo M., Opazo-Ríos L., Marchant V., Marquez-Exposito L., Tejera-Muñoz A., Navarro-González J.F., Droguett A., Ortiz A., et al. Could IL-17A be a novel therapeutic target in diabetic nephropathy? J. Clin. Med. 2020;9:272. doi: 10.3390/jcm9010272. - DOI - PMC - PubMed
    1. Caro-Ordieres T., Marín-Royo G., Opazo-Ríos L., Jiménez-Castilla L., Moreno J.A., Gómez-Guerrero C., Egido J. The coming age of flavonoids in the treatment of diabetic complications. J. Clin. Med. 2020;9:346. doi: 10.3390/jcm9020346. - DOI - PMC - PubMed
    1. Garcia-Fernandez N., Jacobs-Cachá C., Mora-Gutiérrez J.M., Vergara A., Orbe J., Soler M.J. Matrix metalloproteinases in diabetic kidney disease. J. Clin. Med. 2020;9:472. doi: 10.3390/jcm9020472. - DOI - PMC - PubMed
    1. De Bruyne S., Van Dorpe J., Himpe J., Van Biesen W., Delanghe S., Speeckaert M.M., Delanghe J.R. Detection and characterization of a biochemical signature associated with diabetic nephropathy using near-infrared spectroscopy on tissue sections. J. Clin. Med. 2019;8:1022. doi: 10.3390/jcm8071022. - DOI - PMC - PubMed

Publication types

LinkOut - more resources